Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,681 to 4,700 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Treatment Group vs Control Group: Cardiovascular Mortality or Unplanned Hospitalisation/Prolongation of Hospitalisation for Worsening Heart Failure | 345 of 666 317 of 659 | 3.7 points -1.7 to 9.0 | 1,325 | NCT00733343 Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure |
| Treatment Group vs Control Group: First Survived Resuscitation for Any Reason (Evaluation Will Also be Made by the ERC) | 25 of 666 19 of 659 | 0.9 points -1.1 to 2.9 | 1,325 | NCT00733343 Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure |
| Treatment Group vs Control Group: Non-cardiovascular Death | 33 of 666 35 of 659 | -0.4 points -2.8 to 2.1 | 1,325 | NCT00733343 Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure |
| Treatment Group vs Control Group: All Cause Mortality or All Cause Unplanned Hospitalisation/Prolongation of Hospitalisation | 482 of 666 465 of 659 | 1.8 points -3.0 to 6.7 | 1,325 | NCT00733343 Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure |
| Treatment Group vs Control Group: Unplanned Hospitalisation/Prolongation of Hospitalisation Due to Worsening of Heart Failure | 287 of 666 272 of 659 | 1.8 points -3.5 to 7.1 | 1,325 | NCT00733343 Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure |
| Treatment Group vs Control Group: Death From Any Cause | 232 of 666 193 of 659 | 5.5 points 0.5 to 10.5 | 1,325 | NCT00733343 Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure |
| Treatment Group vs Control Group: All Cause Mortality or Unplanned Hospitalisation/Prolongation of Hospitalisation for Worsening Heart Failure | 360 of 666 335 of 659 | 3.2 points -2.2 to 8.6 | 1,325 | NCT00733343 Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure |
| Treatment Group vs Control Group: deaths from any cause | 232 of 666 193 of 659 | 5.5 points 0.5 to 10.5 | 1,325 | NCT00733343 Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure |
| Treatment Group vs Control Group: Adequate Shock in Patients With ICD (Evaluation of Appropriateness Will Also be Made by the Endpoint Review Committee, ERC), Long-Term Atrial Defibrillator Insertion or Cardiovascular Death | 45 of 666 65 of 659 | -3.1 points -6.1 to -0.1 | 1,325 | NCT00733343 Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure |
| Treatment Group vs Control Group: Cardiovascular Death | 199 of 666 158 of 659 | 5.9 points 1.1 to 10.6 | 1,325 | NCT00733343 Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure |
| Treatment Group vs Control Group: serious adverse events | 482 of 666 465 of 659 | 1.8 points -3.0 to 6.7 | 1,325 | NCT00733343 Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure |
| Restrictive vs Liberal: A Composite Endpoint of Cardiac Complications (Other Than MI) at 90 Days Post-randomization: Cardiac Complications Include New Cardiac Arrhythmias That Necessitate New Treatment, New or Worsening Congestive Heart Failure, and Non Fatal Cardiac Arrest | 67 of 678 38 of 647 | 4.0 points 1.1 to 6.9 | 1,325 | NCT03229941 Transfusion Trigger After Operations in High Cardiac Risk Patients |
| PP (Per Protocol) vs ITT (Intention to Treat): Number of Participants With Technical Success | 630 of 632 690 of 692 | -0.0 points -0.9 to 0.8 | 1,324 | NCT02536378 POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE |
| PP (Per Protocol) vs ITT (Intention to Treat): Number of Participants With Procedural Success | 630 of 632 690 of 692 | -0.0 points -0.9 to 0.8 | 1,324 | NCT02536378 POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE |
| PP (Per Protocol) vs ITT (Intention to Treat): Number of Participants With Acute Device Success | 630 of 632 690 of 692 | -0.0 points -0.9 to 0.8 | 1,324 | NCT02536378 POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE |
| PP (Per Protocol) vs ITT (Intention to Treat): deaths from any cause | 1 of 632 3 of 692 | -0.3 points -1.1 to 0.5 | 1,324 | NCT02536378 POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE |
| PP (Per Protocol) vs ITT (Intention to Treat): Number of Participants in Which a Cranial Nerve Injury Occurred | 8 of 632 10 of 692 | -0.2 points -1.5 to 1.2 | 1,324 | NCT02536378 POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE |
| PP (Per Protocol) vs ITT (Intention to Treat): serious adverse events | 27 of 632 14 of 692 | 2.2 points 0.4 to 4.3 | 1,324 | NCT02536378 POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE |
| A+AVD vs ABVD: Number of Participants With Abnormal Clinical Laboratory Values | 662 of 662 658 of 659 | 0.2 points -0.4 to 0.9 | 1,321 | NCT01712490 A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma |
| A+AVD vs ABVD: deaths from any cause | 9 of 662 13 of 659 | -0.6 points -2.1 to 0.8 | 1,321 | NCT01712490 A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma |
Code
curl "https://conductscience.org/api/comparisons/v1?page=235"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=235
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00733343-8fe5a240",
"title": "Treatment Group vs Control Group: Cardiovascular Mortality or Unplanned Hospitalisation/Prolongation of Hospitalisation for Worsening Heart Failure",
"summary": "345 of 666 against 317 of 659; risk difference 3.7 points, 95% interval -1.7 to 9.0; NCT00733343, Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure",
"record": "/library/comparisons/NCT00733343-8fe5a240",
"nct_id": "NCT00733343",
"kind": "outcome",
"participants": 1325,
"risk_difference": {
"value": 0.036986151553678126,
"lower": -0.01681776158141482,
"upper": 0.09048844657312094
},
"group_1": "345 of 666",
"group_2": "317 of 659",
"difference": "3.7 points",
"interval": "-1.7 to 9.0",
"trial_title": "Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure"
},
{
"id": "NCT00733343-a9b30798",
"title": "Treatment Group vs Control Group: First Survived Resuscitation for Any Reason (Evaluation Will Also be Made by the ERC)",
"summary": "25 of 666 against 19 of 659; risk difference 0.9 points, 95% interval -1.1 to 2.9; NCT00733343, Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure",
"record": "/library/comparisons/NCT00733343-a9b30798",
"nct_id": "NCT00733343",
"kind": "outcome",
"participants": 1325,
"risk_difference": {
"value": 0.0087059745633342,
"lower": -0.011092006015265901,
"upper": 0.028828951400611737
},
"group_1": "25 of 666",
"group_2": "19 of 659",
"difference": "0.9 points",
"interval": "-1.1 to 2.9",
"trial_title": "Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=236",
"request_id": "Qh4BIeiNojJLRllt"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
The conductscience.com catalog
One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.
Open Targets
One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.
Open Targets
One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.
ClinicalTrials.gov
One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.
Cellosaurus
One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.
PubMed and NLM's journal list
One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant